Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease | Synapse

January 1, 2020Open Access

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

APO(a)-LRx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease. (Funded by Akcea Therapeutics; ClinicalTrials.gov number, NCT03070782.).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Tsimikas et al. (Wed,) studied this question.

synapsesocial.com/papers/69ab442a91ed9fe11743f389 https://doi.org/https://doi.org/10.1056/nejmoa1905239

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo